as 04-18-2025 1:32pm EST
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
Founded: | 2008 | Country: | United States |
Employees: | N/A | City: | CAMBRIDGE |
Market Cap: | 5.8B | IPO Year: | 2015 |
Target Price: | $124.48 | AVG Volume (30 days): | 1.2M |
Analyst Decision: | Buy | Number of Analysts: | 22 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.07 | EPS Growth: | N/A |
52 Week Low/High: | $73.04 - $121.90 | Next Earning Date: | 05-01-2025 |
Revenue: | $508,824,000 | Revenue Growth: | 104.04% |
Revenue Growth (this year): | 45.7% | Revenue Growth (next year): | 31.83% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Haviland Kate | BPMC | CHIEF EXECUTIVE OFFICER | Apr 1 '25 | Sell | $86.89 | 2,498 | $216,460.72 | 165,929 | |
Rossi Christina | BPMC | CHIEF OPERATING OFFICER | Mar 24 '25 | Sell | $95.02 | 2,274 | $216,075.48 | 69,266 | |
Albers Jeffrey W. | BPMC | Director | Mar 12 '25 | Sell | $88.00 | 7,500 | $658,500.00 | 152,396 | |
Albers Jeffrey W. | BPMC | Director | Mar 5 '25 | Sell | $88.80 | 5,766 | $512,020.80 | 152,396 | |
Landsittel Michael | BPMC | CHIEF FINANCIAL OFFICER | Mar 5 '25 | Sell | $88.80 | 5,284 | $469,219.20 | 72,924 | |
Lee Philina | BPMC | CHIEF COMMERCIAL OFFICER | Mar 5 '25 | Sell | $88.80 | 3,733 | $331,490.40 | 41,996 | |
Durso-Bumpus Debra | BPMC | CHIEF PEOPLE OFFICER | Mar 5 '25 | Sell | $88.80 | 5,157 | $457,941.60 | 49,606 | |
Rossi Christina | BPMC | CHIEF OPERATING OFFICER | Mar 5 '25 | Sell | $88.80 | 6,495 | $576,756.00 | 69,266 | |
Namouni Fouad | BPMC | PRESIDENT, R & D | Mar 5 '25 | Sell | $88.80 | 6,489 | $576,223.20 | 75,781 | |
Hurley Ariel | BPMC | PRINCIPAL ACCOUNTING OFFICER | Mar 5 '25 | Sell | $88.80 | 1,326 | $117,748.80 | 16,944 |
BPMC Breaking Stock News: Dive into BPMC Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
PR Newswire
19 days ago
Insider Monkey
20 days ago
Insider Monkey
24 days ago
Insider Monkey
a month ago
TipRanks
a month ago
MT Newswires
a month ago
Simply Wall St.
a month ago
The information presented on this page, "BPMC Blueprint Medicines Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.